Retention of the Alzheimer's Amyloid Precursor Fragment C99 in the Endoplasmic Reticulum Prevents Formation of Amyloid beta -Peptide*

William A. MalteseDagger §, Susan WilsonDagger , Yizheng Tan, Susanna Suomensaari||, Sukanto Sinha||, Robin Barbour||, and Lisa McConlogue||

From the Dagger  Department of Biochemistry and Molecular Biology, Medical College of Ohio, Toledo, Ohio 43614, the  Weis Center for Research, Pennsylvania State College of Medicine, Danville, Pennsylvania 17822, and || Elan Pharmaceuticals, South San Francisco, California 94080

Received for publication, August 10, 2000, and in revised form, March 5, 2001

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

gamma -Secretase is a membrane-associated endoprotease that catalyzes the final step in the processing of Alzheimer's beta -amyloid precursor protein (APP), resulting in the release of amyloid beta -peptide (Abeta ). The molecular identity of gamma -secretase remains in question, although recent studies have implicated the presenilins, which are membrane-spanning proteins localized predominantly in the endoplasmic reticulum (ER). Based on these observations, we have tested the hypothesis that gamma -secretase cleavage of the membrane-anchored C-terminal stump of APP (i.e. C99) occurs in the ER compartment. When recombinant C99 was expressed in 293 cells, it was localized mainly in the Golgi apparatus and gave rise to abundant amounts of Abeta . Co-expression of C99 with mutant forms of presenilin-1 (PS1) found in familial Alzheimer's disease resulted in a characteristic elevation of the Abeta 42/Abeta 40 ratio, indicating that the N-terminal exodomain of APP is not required for mutant PS1 to influence the site of gamma -secretase cleavage. Biogenesis of both Abeta 40 and Abeta 42 was almost completely eliminated when C99 was prevented from leaving the ER by addition of a di-lysine retention motif (KKQN) or by co-expression with a dominant-negative mutant of the Rab1B GTPase. These findings indicate that the ER is not a major intracellular site for gamma -secretase cleavage of C99. Thus, by inference, PS1 localized in this compartment does not appear to be active as gamma -secretase. The results suggest that presenilins may acquire the characteristics of gamma -secretase after leaving the ER, possibly by assembling with other proteins in peripheral membranes.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Amyloid beta -peptide (Abeta )1 is the major molecular component of the cerebral amyloid plaques associated with Alzheimer's disease. The cellular pathways involved in the biogenesis of Abeta have been the subject of intense investigation since the discovery that Abeta originates from intracellular endoproteolytic processing of a type I membrane-spanning glycoprotein termed amyloid precursor protein (APP) (1-4). Extensive studies have established that APP can be processed via two alternative routes, one of which yields the 4-kDa Abeta , whereas the other yields a truncated non-amyloidogenic peptide (p3) (5, 6). In most cells the non-amyloidogenic pathway predominates. The first step involves the cleavage of APP within the Abeta domain by a protease termed alpha -secretase (7-9). After release of the N-terminal exodomain, the residual 83-amino acid membrane-spanning C-terminal fragment is further processed by another protease termed gamma -secretase to remove the cytoplasmic tail and generate p3 (6, 10). Because the latter cleavage occurs within the predicted membrane spanning region of APP (11-13), gamma -secretase is generally thought to be an intramembrane protease. In the alternative amyloidogenic pathway, APP is initially cleaved proximal to the Abeta sequence by beta -secretase, leaving a 99-amino acid C-terminal fragment (C99) that contains the intact Abeta sequence and the cytoplasmic tail (1, 14, 15). Thus, when gamma -secretase cuts the latter substrate, Abeta is released. Cells can generate distinct species of Abeta that differ in chain length (e.g. Abeta 40 and Abeta 42). It remains unclear whether the different forms of Abeta arise through the action of separate gamma -secretases (11, 16, 17) or instead reflect the ability of a single enzyme to cleave C99 at more than one site (18). Although Abeta 40 is produced in greater abundance than Abeta 42, the longer peptide has particular significance for Alzheimer's disease pathology, since it readily forms insoluble aggregates and accumulates in neuritic plaques (19-21).

A number of reports have provided information about the subcellular compartments where APP is cleaved by the alpha - and beta -secretases. Metalloproteases that function as alpha -secretases (22, 23) appear to operate on APP at or near the cell surface (9, 24, 25). On the other hand, beta -secretase cleavage occurs predominantly in intracellular membrane compartments such as the Golgi apparatus (26-28) and endosomes (29-31). The latter findings have been verified in studies of newly identified aspartic proteases that function as beta -secretase (32-35). The identity of gamma -secretase remained elusive until a recent series of studies implicated the serpentine membrane-spanning proteins, presenilin-1 (PS1) and presenilin-2 (PS2), as catalytic components of this enzyme. Mutations in the presenilins have been linked to familial forms of Alzheimer's disease that are characterized by elevations of the Abeta 42/Abeta 40 ratio (36-39). It now appears that presenilins may be unique aspartyl proteases that can function as gamma -secretase (40-43) or play an essential role in regulating gamma -secretase activity (44, 45). The subcellular location of the gamma -secretase cleavage step has not been established definitively, but several studies (46-48) have suggested that it occurs in the ER, where most of the presenilin is localized (49-51). If this is true, it would imply that the C83 and C99 fragments generated by alpha -secretase and beta -secretase in the plasma membrane and Golgi/endosomal compartments, respectively, must be transported back to the ER for the final cleavage by gamma -secretase. However, the evidence supporting gamma -secretase processing of APP in the ER is not definitive. For example, in neurons Abeta 42 is found in the ER, whereas Abeta 40 is localized in the trans-Golgi network (52), but it is difficult to determine if the steady-state distribution of the Abeta peptides reflects the primary site where they are generated. Other evidence pointing to the ER as a site of gamma -secretase activity centers around the observation that intracellular production of total Abeta (46) or Abeta 42 (47) can continue unchecked when ER right-arrow Golgi transport is blocked by brefeldin A. However, the interpretation of these observations is complicated by the fact that brefeldin A causes mixing of various membrane compartments, i.e. the Golgi apparatus merges with the ER and the trans-Golgi network fuses with endosomes (53, 54). A final line of evidence supporting the existence of gamma -secretase activity in the ER comes from a report by Soriano et al. (48), who found that secretion of Abeta 40 and Abeta 42 was not markedly reduced when APP was retained in the ER by fusing the extracellular and transmembrane domains with the cytoplasmic region of the T cell antigen receptor CD3gamma chain. However, from this study it is not entirely clear whether the susceptibility of the chimeric APP/CD3gamma substrate to the ER protease accurately represents the behavior of the native APP or C99. Indeed, there is considerable evidence that the cytoplasmic domain of APP, which was removed in the aforementioned study, contains important sorting determinants (55) and sequence elements required for interaction with proteins like X11 (56) and nicastrin (57), which may influence APP processing and Abeta secretion.

In the present study we examined directly the contribution of the ER compartment to gamma -secretase processing of the membrane-anchored C99 stump of APP in transfected cells, using two different strategies. The first strategy involved the addition of minimal tetrapeptide extensions to the C terminus of C99 to either retain the protein in the ER (KKQN) or allow its trafficking to the Golgi and other distal compartments (QLQN). The second strategy entailed the co-expression of C99 with wild-type or dominant-negative mutant versions of the Rab1B GTPase, which controls vesicular transport of proteins from the ER to the Golgi compartment. The results show that when C99 was allowed to leave the ER, it was a good substrate for gamma -secretase and responded to co-expression of PS1 FAD variants with typical elevations of the Abeta 42/Abeta 40 ratio. In contrast, cellular production of both Abeta 40 and Abeta 42 was almost completely eliminated when C99 was retained in the ER, where most of the expressed PS1 was localized. These findings lead us to conclude that the ER is not a major intracellular site for gamma -secretase activity and, by inference, that the large pool of PS1 that is typically localized in this compartment is not catalytically active as gamma -secretase. The results also indicate that the interactions that occur between PS1 and APP to influence the site of gamma -secretase cleavage (i.e. the production of long versus short forms of Abeta ) do not require the N-terminal exodomain of APP.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Expression Vectors-- The pohCk751sw mammalian expression vector has been described previously (58). It encodes the Swedish variant of APP751 (SwAPP) which contains a dual amino acid change (K651N,M652L) that increases the susceptibility of the protein to processing by beta -secretase (59-61). The cDNA encoding SwAPP was modified by standard PCR techniques using Pfu polymerase (Stratagene) and appropriate primers so that the last four amino acids of the protein were changed from QMQN to KKQN. By using the pohCK751sw template, PCR was also used to generate cDNA constructs encoding the APP-derived C99 fragment, with the addition of a Myc epitope (EQKLISEEDL) followed by either QLQN or KKQN at the C terminus. In generating the C99 DNA constructs, the oligonucleotide primers were designed to add a KpnI restriction site and an ATG start codon to the 5' end of the cDNA and a BamHI site to the 3' end. The PCR products were digested with KpnI and BamHI and ligated into the pCMV5 mammalian expression vector (62), resulting in plasmids designated pCMV5-C99(QLQN) and pCMV5-C99(KKQN).

To generate Sindbis virus expression vectors, the cDNA inserts encoding C99(QLQN) and C99(KKQN) were excised from the pCMV5 vectors with KpnI and BamHI and cloned into the pKF3 enforcement vector (Takara/PanVera, Madison, WI) to pick up XbaI and SmaI sites at the 5' and 3' ends, respectively. The latter enzymes were then used to excise the C99 inserts and clone them between the XbaI and StuI sites of the pSinRep5 vector (Invitrogen). The final constructs were designated pSinRep5-C99(QLQN) and pSinRep5-C99(KKQN). All constructs were determined to be correct by automated DNA sequencing, using an ABI 377 system.

The mammalian expression vectors, pCMV5Rab1B(wt) and pCMV5Rab1B(N121I), which encode Myc epitope-tagged versions of Rab1B, have been described previously (58, 63). The vectors, pohCkPS1, pohCkPS1(M146L), and pohCkPS1(L286V), which encode wt and FAD variant forms of presenilin-1, have also been described in an earlier report (64).

Transfection of Cultured 293 Cells-- Human embryonal kidney cells (line 293) were obtained from American Type Culture Collection (Manassas, VA) and were maintained at 37 °C in a 5% CO2 atmosphere in Dulbecco's modified Eagle's medium (DMEM) containing 10% (v/v) fetal bovine serum (FBS). Tet-offTM 293 cells were obtained form CLONTECH (Palo Alto, CA) and maintained in DMEM with 10% tetracycline-free FBS and 100 µg/ml geneticin (G418). Cells were plated in 60-mm dishes at 5 × 105 cells/dish on the day before transfection.

In studies of SwAPP or C99 expression and processing, cells were transfected with pohCk751sw, pohCk751sw(KK), pCMV5-C99(QLQN) or pCMV5-C99(KKQN), using LipofectAMINE Plus reagent according to the protocol recommended by the manufacturer (Life Technologies, Inc.). The same approach was used in studies involving co-transfection of cells with pCMV5-C99(QLQN) and either pCMV5Rab1B(wt) or pCMV5Rab1B(N121I). For some studies, the Myc-tagged Rab1B(wt) and Rab1B(N121I) cDNA constructs were subcloned into pTRE (CLONTECH) to permit suppression of gene expression in 293 Tet-off cells by addition of doxycycline.

In studies aimed at assessing the effects of PS1 on C99 processing, parallel cultures were co-transfected with pCMV5-C99(QLQN) combined with pohCkPS1, pohCkPS1(M146L), or pohCkPS1(L286V), using Superfect transfection reagent (Qiagen, Valencia, CA) according to the protocol recommended by the manufacturer.

Protein Expression in Cultured Neurons-- Cultures of NT2N neurons were derived from Ntera2 teratocarcinoma cells (65) by treatment with retinoic acid and mitotic inhibitors as described previously (66). The Sindbis virus system (67, 68) was used to express C99(QLQN) or C99(KKQN) in NT2N neurons. In brief, pSinRep5-C99(QLQN) and pSinRep5-C99(KKQN) were linearized with XhoI, and RNA was generated by in vitro transcription. The RNA was introduced into baby hamster kidney cells by electroporation, along with dh26S helper virus RNA. The culture medium enriched in recombinant virus was harvested 24 h after the co-transfection, and the virus was used to infect NT2N cells. For each 60-mm culture, 150 µl of virus-conditioned medium was mixed with 300 µl of minimal essential medium with 1% FBS. Cells were incubated for 1 h at 37 °C, and then 4 ml of fresh minimal essential medium + 1% FBS was added. Cells and medium were harvested for assay of C99 and Abeta after 15 h.

Metabolic Labeling and Immunoprecipitation of APP-- Beginning 24 h after transfection, 293 cells were pulse-labeled for 15 min at 37 °C with 1 ml of methionine-free DMEM containing 100 µCi of [35S]methionine/cysteine (Trans-label, 1100-1200 Ci/mmol, ICN Inc.). The cells were then washed twice with PBS and subjected to a 45-min chase in DMEM containing 10% FBS, 2 mM methionine, and 2 mM cysteine. Cells were harvested from parallel cultures at the end of the pulse and chase periods, and APP was immunoprecipitated from cell lysates as described previously (58). Immature and mature forms of APP were separated by SDS-PAGE and visualized by fluorography by using established procedures (69).

Immunoblot Analysis-- For immunoblot analysis of APP or PS1, cells were lysed in PBS containing 1% (v/v) Triton X-100. Aliquots of cell lysate or conditioned medium were mixed with an equal volume of 2× sample buffer containing 8 M urea, 4% SDS w/v, 10% 2-mercaptoethanol v/v, 20% glycerol v/v, and 125 mM Tris-HCl, pH 6.8. Proteins were subjected to SDS-PAGE, using 10% polyacrylamide gels for analysis of PS1 and 6.5% polyacrylamide gels for analysis of APP. For analysis of C99 and Rab1B, samples were prepared as described above, except that SDS-PAGE was performed on pre-cast Tricine 10-20% polyacrylamide gradient gels (NOVEX, San Diego, CA). Proteins were transferred to Immobilon-P (Millipore Corp, Bedford, MA), and the membranes were preincubated for 1 h in blotting solution (PBS containing 5% w/v powdered milk and 0.05% v/v Tween 20). Immunoblotting was carried out as described previously (27, 58). Intracellular APP and total secreted forms of APP (s-APPtotal) were detected with monoclonal antibody 8E5 (70). The soluble exodomain fragments released from SwAPP as a result of alpha -secretase cleavage (s-APPalpha ) or beta -secretase cleavage (s-APPbeta ) were detected with antibodies 2H3 (27) and SW192 (31), respectively. PS1 was detected with an antibody against residues 1-79 from the N terminus of the protein (71), purchased from Zymed Laboratories Inc. Laboratories (South San Francisco, CA). C99 was detected with the following monoclonal antibodies: 9E10, which recognizes the Myc epitope (Calbiochem), 6E10, which recognizes residues 1-12 of the Abeta sequence (Senetek, Napa, CA), or 13G8, which recognizes the last 20 residues at the C terminus of APP (gift from P. Seubert and D. Schenk, Elan Pharmaceuticals, South San Francisco, CA). Rab1B was detected with an affinity-purified polyclonal antibody from Zymed Laboratories Inc.. Standard chemiluminescent detection was carried out with the ECL kit (Amersham Pharmacia Biotech), using horseradish peroxidase-conjugated goat anti-rabbit IgG or goat anti-mouse IgG (Bio-Rad) at 1:3000 v/v dilution.

For high sensitivity immunoblot analysis of total Abeta , an aliquot of conditioned medium or cell lysate was diluted 3:1 with 4× concentrated SDS sample buffer and loaded on a Tricine 10-20% polyacrylamide gradient gel. Proteins were transferred to Immobilon-P at 4 °C at 400 mA for 3 h, with a transfer buffer consisting of 12 mM Tris, 96 mM glycine, 20% methanol, pH 8.3. The membranes were then incubated with the 6E10 antibody followed sequentially by biotinylated goat anti-mouse IgG and streptavidin conjugated to horseradish peroxidase(Bio-Rad). Bound HRP was detected with SuperSignal reagent (Pierce).

ELISAs for Abeta -- Conditioned medium (2 ml total) was collected from each culture 24 h after transfection. The concentrations of Abeta peptides were determined by sandwich-type ELISAs as described (27), with the following modifications. Polystyrene 96-well assay plates (Costar) were coated with the antibody specific for Abeta 40, 2G3, at 10 µg/ml, or with the antibody specific for Abeta 42, 21F12, at 5 µg/ml. Samples were incubated on the plates overnight at 4 °C. The plates were washed with Tris-buffered saline containing 0.05% Tween 20 (TTBS) and then incubated with biotinylated reporter antibody. The 3D6 monoclonal antibody (specific for residues 1-5 of Abeta ) was used as the reporter in the assays of cells transfected with full-length APP (Fig. 3). Monoclonal antibody 266 (specific for residues 13-28 of Abeta ) was used as the reporter in the studies where C99 was co-expressed with PS1 (Fig. 11). The 6H9 monoclonal antibody (see below) was used as the reporter in the assays of medium from cells expressing C99 with or without an ER-retention signal (Fig. 7). The immunogen for the 6H9 monoclonal antibody was prepared by coupling a peptide encoding Abeta -(17-28) plus a C-terminal extension of Gly-Gly-Cys to sheep anti-mouse IgG using epsilon -maleimidocaproic acid N-hydroxysuccinimide. 100 µg of the immunogen was injected into mice in Freund's adjuvant, and hybridomas were generated from the highest titer mouse using standard methods. The reporter antibodies were added at a final concentration of 0.25 µg/ml in specimen diluent (17 mM NaPO4, pH 7.4, 7.7 mM sodium azide, 100 mM NaCl, 0.05% Triton X-405, 6 mg/ml bovine serum albumin). The plates were incubated at room temperature for 1 h and washed with TTBS. Streptavidin-alkaline phosphatase (Roche Molecular Biochemicals, 1000 units/ml) was added at a dilution of 1:1000 in specimen diluent, and the plates were incubated for 1 h at room temperature. The plates were then washed in TTBS, and exposed to fluorescent substrate as described (72). Synthetic Abeta -(1-40) or -(1-42) peptides were used as standards. The signals were read in a CytoFluor 2350 (Millipore Corp., Bedford, MA) at 360/460 nm.

Immunofluorescence Microscopy-- Cells were plated on laminin-coated coverslips in 60-mm dishes and transfected with the indicated plasmids as described earlier. After 24 h, the cells were fixed for 15 min in 3% (w/v) paraformaldehyde in PBS and permeabilized with 0.1% (v/v) Triton X-100 in PBS for 2 min. Cells were blocked with 0.1% (w/v) bovine serum albumin in PBS for 30 min and subjected to immunofluorescence staining as described previously (58). Detection of expressed C99(QLQN) or C99(KKQN) was accomplished with the 9E10 mouse monoclonal anti-Myc antibody followed by Texas Red-conjugated goat anti-mouse IgG (Molecular Probes, Eugene, OR). Where indicated, cells expressing C99 were also incubated with rabbit polyclonal antibodies against either calreticulin (Affinity BioReagents Inc, Golden, CO) or Rab6 (Santa Cruz Biotechnology, Santa Cruz, CA), followed by FITC-conjugated goat anti-rabbit IgG (Sigma). In one case, cells expressing C99 were incubated with a rabbit polyclonal anti-Myc antibody (Upstate Biotechnology, Inc., Lake Placid, NY) combined with a mouse monoclonal antibody H4B4 against the lysosomal membrane protein LAMP-2 (73), obtained from the Developmental Studies Hybridoma Bank, University of Iowa. To visualize PS1, cells were incubated with an affinity-purified rabbit IgG (Zymed Laboratories Inc., South San Francisco, CA) that recognizes the full-length protein and the N-terminal fragment (71). The secondary antibody was Texas Red-conjugated goat anti-rabbit IgG (Molecular Probes, Eugene, OR). Where C99 was co-expressed with PS1, C99 was detected with the 9E10 monoclonal antibody against the Myc epitope, followed by FITC-conjugated goat anti-mouse IgG (Sigma). Photomicrographs were taken with a Nikon Eclipse 800 fluorescence microscope equipped with a digital camera. Images were merged and pseudo-colored through the use of ImagePro software (Phase 3 Imaging Systems, Glen Mills, PA).

Proteolytic Cleavage of SREBP-- For studies of the intracellular endoproteolytic processing of sterol regulatory element-binding protein type 2 (SREBP2), the mammalian expression vector pTK-HSV-BP2 was obtained from the American Type Culture Collection.

The latter encodes an N-terminal HSV epitope-tagged version of SREBP2 under the control of the thymidine kinase promoter (74). Parallel 10-cm dishes of 293 cells were co-transfected with 2 µg of pTK-HSV-BP2 combined with either 2 µg of pCMV5Rab1B(wt) or pCMV5Rab1B(N121I). Immediately after transfection, cultures were fed with DMEM containing 10% delipidated FBS and 25 µM lovastatin to promote sterol depletion and SREBP cleavage. Cells were collected 20 h after transfection, with addition of 25 µg/ml N-acetyl-leucinal-luecinal-norleucinal to the medium 3.5 h prior to harvest. Cells from four dishes were combined and fractionated into membrane components and nuclear extracts as described by Hua et al. (75). Aliquots of protein from the membrane fraction (100 µg) and nuclear extract (185 µg) were subjected to SDS-PAGE and immunoblot analysis using a monoclonal antibody against the HSV epitope (Novagen Inc., Madison, WI) to detect the SREBP2 full-length protein and the N-terminal fragment. Immunoblots were scanned and quantified with a Kodak 440CF Image Station.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Addition of a Di-lysine Motif to SwAPP Prevents Golgi-dependent Maturation of the Protein-- Numerous studies have established that type I transmembrane proteins containing C-terminal KKXX motifs are retrieved from early Golgi and intermediate compartments and retained in the ER (76-78). To determine whether the addition of such a motif to the cytoplasmic tail of APP would prevent the protein from being transported beyond the cis-Golgi compartment, plasmids encoding SwAPP with the normal C-terminal ending (QMQN) or a modified sequence, KKQN, were transfected into 293 cells, and the transiently expressed proteins were monitored by pulse-chase analysis of the [35S]methionine-labeled protein. Radiolabeled APP was immunoprecipitated from parallel transfected 293 cell cultures, either immediately after a 15-min pulse with [35S]methionine or after a 45-min chase to allow time for nascent APP to undergo ER right-arrow Golgi transport and oligosaccharide maturation. Consistent with previous observations, SwAPP migrates as two major bands with the slower form (~130 kDa) representing the mature protein that has undergone O-glycosylation in the medial-late Golgi compartment and the faster form (~108 kDa) representing the immature form of the protein that is localized predominantly in the ER (58, 79, 80). As shown in Fig. 1A, the nascent 108-kDa form of SwAPP was the predominant radiolabeled protein detected in the cultures immediately after the pulse. Conversion of immature SwAPP to the mature form was readily detected after the 45-min chase in the cells overexpressing SwAPP with the normal C-terminal sequence but not in the cells expressing the protein with the di-lysine ER retention motif. As determined previously for SwAPP (58), the 108-kDa form of SwAPP with the KKQN motif was sensitive to digestion with endoglycosidase H (not shown), indicating that it contains N-linked high mannose oligosaccharides typical of immature glycoproteins that have not yet been trimmed by alpha 1,2-mannosidase II in the Golgi compartment (81). The ability of the KKQN motif to retain SwAPP in the ER was confirmed by SDS-PAGE and immunoblot analysis to monitor steady-state levels of mature versus immature protein (Fig. 1B). When the C terminus of SwAPP was changed to KKQN, the amount of the mature form was substantially reduced.


View larger version (43K):
[in this window]
[in a new window]
 
Fig. 1.   Addition of a di-lysine ER retention motif prevents Golgi-dependent maturation of SwAPP in 293 cells. A, cells were transiently transfected with vectors encoding SwAPP or the same protein in which the last amino acids were altered to form a KKQN motif. Parallel cultures that were not transfected (lanes marked None) were used to determine the background levels of endogenous APP expressed in the 293 cells. Pulse-chase analysis of APP processing was performed 24 h later. Cells were harvested immediately after pulse-labeling with [35S]methionine (0 min) or after the chase with unlabeled methionine (45 min) as indicated. APP was immunoprecipitated and subjected to SDS-PAGE and fluorography. The positions of the mature O-glycosylated form of APP (m) and the immature protein (i) are indicated by the arrows. B, immunoblot analyses were performed on aliquots of the cell lysates from the cultures harvested at the end of the chase period to determine the steady-state levels of immature and mature intracellular APP, using the 8E5 monoclonal antibody, which recognizes all forms of APP.

Addition of a Di-lysine Motif to SwAPP Inhibits the Secretion of Soluble Exodomain Fragments and Abeta Peptides-- As mentioned earlier, cleavage of APP by alpha -secretase occurs at the cell surface, whereas alternative cleavage by beta -secretase appears to take place in late Golgi or endosomal compartments. Hence, one would predict that retention of SwAPP in the ER would prevent the substrate from coming into contact with both alpha - and beta -secretase. To test this prediction, we compared the relative amounts of the soluble exodomain fragments (s-APP) released into the medium from cells expressing SwAPP with or without the C-terminal di-lysine motif (Fig. 2). The results show that there was an 85-90% reduction in the amount of s-APPalpha and s-APPbeta released from the cells expressing SwAPP with the ER retention signal. Essentially identical results were obtained when the immunoblot values for secreted exodomain fragments were normalized to the values for total SwAPP expressed in the transfected cells (not shown).


View larger version (36K):
[in this window]
[in a new window]
 
Fig. 2.   Addition of the ER-retention signal to SwAPP causes a decrease in secretion of soluble exodomain fragments (s-APP) released by alpha -secretase or beta -secretase. HEK293 cells were transfected with vectors encoding SwAPP with the normal C-terminal ending (SwAPP) or the di-lysine ER retention motif (SwAPP-KKQN). Parallel cultures that were not transfected (None) were used to assess background levels of s-APP in the medium. The medium was removed from all cultures 24 h after transfection. Immunoblot assays were performed on equal aliquots of medium using the following: A, monoclonal antibody 8E5, which detects both s-APPalpha and s-APPbeta (s-APPTotal); B, polyclonal antibody SW192, which detects only s-APPbeta derived from the Swedish variant of APP; or C, monoclonal antibody 2H3, which detects s-APPalpha . The results (mean ± S.E.) from separate determinations on three cultures are shown in the bar graphs next to the representative blots. Intracellular levels of expressed SwAPP and SwAPP(KKQN) were very similar, so that essentially identical results were obtained when the extracellular s-APP values were normalized to the intracellular levels of SwAPP (not shown).

Because the preceding findings indicated that SwAPP(KKQN) was not efficiently cleaved by beta -secretase, we postulated that the amount of Abeta produced by cells expressing this construct would be significantly diminished. This hypothesis was tested by measuring the concentrations of Abeta released into the culture medium using ELISAs specific for long and short forms of the peptide. As shown in Fig. 3, addition of the KKQN motif to SwAPP caused a 75-80% decrease in the amount of Abeta 40 released into the medium. The amount of Abeta 42 was similarly reduced, so that percentage of Abeta 42 relative to Abeta 40 (~5%) was not significantly altered.


View larger version (12K):
[in this window]
[in a new window]
 
Fig. 3.   Addition of ER retention signal to SwAPP causes a reduction of both Abeta 40 and Abeta 42. HEK293 cells were transfected with vectors encoding SwAPP with the normal C-terminal ending (SwAPP) or the di-lysine ER retention motif (SwAPP-KKQN). Aliquots of conditioned medium were subjected to ELISA to determine the concentrations of Abeta 40 and Abeta 42. Each value is a mean (±S.E.) from assays performed on two parallel cultures.

Retention of the APP C99 Domain in the ER Decreases the Production of Abeta -- The foregoing studies indicate that the biogenesis of Abeta from full-length SwAPP is greatly diminished when the latter is retained in the ER. The decline in Abeta seen in these studies is probably due to the reduced contact of the SwAPP substrate with active beta -secretase, based on the parallel reduction in the output of s-APPbeta (Fig. 2B). The small amount of residual Abeta produced in the cells overexpressing SwAPP(KKQN) could be related to incomplete retention of the protein in the ER, possibly due to saturation of coatomer binding sites (82). Alternatively, it could reflect the presence of gamma -secretase activity in the ER, possibly allowing a small pool of SwAPP to be transported to the beta -secretase compartment after removal of the C-terminal tail containing the KKQN motif. In light of these uncertainties, we felt it was important to obtain a more direct assessment of the activity of gamma -secretase in the ER. Toward this end, we generated a C99(KKQN) construct that corresponds to the C-terminal portion of APP that remains after beta -secretase cleavage. To facilitate detection, we added a short Myc epitope tag to the C terminus, followed by the ER retention motif, KKQN (Fig. 4A). To verify that the C-terminal additions did not in themselves affect gamma -secretase cleavage, an identical construct was generated with QLQN instead of KKQN following the Myc tag, i.e. C99(QLQN). Immunoblot analyses using different antibodies to detect epitopes on the N-terminal or C-terminal ends of the molecule indicated that both C99(QLQN) and C99(KKQN) were transiently expressed in an intact form at similar levels in 293 cells (Fig. 4B). However, the cells expressing the construct with the di-lysine ER retention motif showed a striking decrease in the amount of Abeta deposited into the culture medium (Fig. 4C). To verify that the decrease in extracellular Abeta reflects a decrease in the biogenesis of the peptide rather than a block in its secretion, we also measured intracellular Abeta in cells expressing the two C99 constructs (Fig. 4C). Consistent with the absence of Abeta in the medium, intracellular Abeta was nearly undetectable in cells expressing C99(KKQN).


View larger version (38K):
[in this window]
[in a new window]
 
Fig. 4.   Addition of an ER retention signal prevents Abeta production from the C99 C-terminal fragment of APP. A, general description of the C99 protein constructs showing relative positions of the Abeta sequence, gamma -secretase cleavage sites, Myc epitope, and terminal tetrapeptide extensions. The domains recognized by the 6E10 and 13G8 antibodies are also indicated. B, immunoblots showing comparative expression levels of C99(QLQN) and C99(KKQN) in equal aliquots of cell lysate from 293 cells harvested 24 h after transfection. The antibodies used are indicated below each panel. Standard ECL was used for detection of bound IgG. C, immunoblots with the 6E10 antibody show that total Abeta was reduced in the medium and cell lysate from cells expressing C99(KKQN), compared with cells expressing C99(QLQN). The samples consisted of 2% of the total cell lysate and 0.05% of the 48-h conditioned medium. The standard was 4 ng of Abeta 40 (Quality Controlled Biochemicals, Inc., Hopkinton, MA). In the panel on the left side, equal aliquots of cell lysate were blotted with the 6E10 antibody to verify that expression levels of C99(KKQN) and C99(QLQN) were comparable. Bound IgGs were detected using the high sensitivity method described under "Experimental Procedures." The Abeta signals cannot be compared directly with the C99 signals, because of variations in the exposure time (1 s for C99 and 2 min for Abeta ). The results are representative of two separate experiments. D and E, NT2N neurons were infected with Sindbis virus encoding C99(QLQN), C99(KKQN), or virus without insert (none), as indicated. The cells were then labeled for 7 h with [35S]methionine (100 µCi/ml), and Abeta was immunoprecipitated from 0.5 ml of culture medium (E). To verify that similar levels of C99 expression were obtained in the cells, equal aliquots of cell lysate were subjected to immunoblot assay, using the 13G8 antibody (D). Similar results were obtained in two separate experiments.

To confirm that these observations were pertinent to human neurons as well as 293 cells, the C99(QLQN) and C99(KKQN) constructs were subcloned into Sindbis virus vectors and expressed in stable differentiated NT2N neurons. As shown in Fig. 4, D and E, radiolabeled Abeta was clearly detected above background levels in medium from NT2N cultures expressing C99(QLQN) but not in cultures expressing similar amounts of C99(KKQN).

Subcellular Localization of C99-- When 293 cell lysates were subjected to differential centrifugation, the expressed C99(QLQN) and C99(KKQN) polypeptides were found predominantly in membrane-enriched particulate fractions (not shown). However, because C99 lacks the glycosylation sites of the APP exodomain, it was not possible to verify retention of C99(KKQN) in the ER by monitoring Golgi-dependent post-translational modifications of the protein. As an alternative, we compared the subcellular distribution of C99(QLQN) and C99(KKQN) with the distribution of an ER marker protein, calreticulin (83), by immunofluorescence analysis. As shown in Fig. 5A, C99(QLQN) was concentrated in a discrete region adjacent to the nucleus, with almost no overlap with calreticulin. In contrast, C99(KKQN) was localized in a perinuclear ring and a diffuse reticular network throughout the cytoplasm. The staining pattern of C99(KKQN) was nearly identical to that of the calreticulin marker (Fig. 5A). In the absence of the ER retention signal, most of the overexpressed C99(QLQN) was co-localized with Rab6 GTPase, which is known to function within the medial and trans-Golgi compartments (84, 85) (Fig. 5B). Consistent with its retention in the ER, C99(KKQN) showed little or no co-localization with Rab6 (Fig. 5B). It should be noted that in the merged image of C99(QLQN) with Rab6 (Fig. 5B), a small portion of the C99 did not overlap with the Golgi marker. This non-Golgi pool of C99 may be localized in the endocytic compartment, based on partial overlap of C99(QLQN) with LAMP-2, a marker for late endosomes and lysosomes (73) (Fig. 5C).


View larger version (58K):
[in this window]
[in a new window]
 
Fig. 5.   Immunofluorescence localization of C99 proteins with or without an ER retention motif. Cells were fixed 24 h after being transfected with expression vectors encoding either C99(QLQN) or C99(KKQN) (see Fig. 4). Localization of C99 was determined in A and B with a mouse monoclonal antibody against the Myc epitope and in C with a rabbit polyclonal antibody against the Myc epitope. Texas Red-conjugated goat anti-mouse or anti-rabbit IgGs were used to detect the anti-Myc primary antibodies (red). Cells were also incubated with affinity-purified rabbit polyclonal antibodies against calreticulin (A) or Rab6 (B), or with a mouse monoclonal antibody against LAMP-2 (C), (followed by appropriate FITC-conjugated goat anti-rabbit or anti-mouse IgGs) to highlight the ER, Golgi, and endosome/lysosome compartments, respectively (green).

Subcellular Localization of C99 in Relation to PS1-- Because PS1 has been proposed as a possible gamma -secretase or a critical interacting protein controlling gamma -secretase activity, we decided to compare the subcellular distribution of C99(QLQN) and C99(KKQN) with the distribution of PS1. Previous studies have established that endogenous PS1 is localized predominantly in the perinuclear region and the ER, with very little protein localized in post-Golgi compartments (50, 86). The staining around the nuclear envelope has been attributed to the full-length protein, whereas the protein in the ER appears to arise from the N-and C-terminal fragments (50). In Fig. 6A we examined the distribution of overexpressed PS1, using a previously characterized antibody that recognizes the full-length protein and the N-terminal fragment. We observed both a perinuclear ring and a predominant ER staining pattern. The latter was verified in separate studies where there was good coincidence between PS1 and the ER markers, protein disulfide isomerase, and calnexin (not shown). Identical results were obtained when the localization studies were repeated with an antibody against the C-terminal loop domain of PS1 (not shown), consistent with the notion that the N-terminal and C-terminal polypeptides remain together after endoproteolytic cleavage of PS1 (51, 87). As expected, based on its demonstrated retention in the ER (Fig. 5), C99(KKQN) was localized almost entirely in compartments that contained PS1 (Fig. 6A). In contrast, the staining pattern for C99(QLQN), which was localized mainly in the Golgi and endosomal compartments, showed much less overlap with PS1 (Fig. 6B). Thus, the sharp decline in Abeta production that we observed when C99 was retained in the ER (Fig. 4) occurred despite an increased co-localization of C99(KKQN) with PS1.


View larger version (34K):
[in this window]
[in a new window]
 
Fig. 6.   Intracellular localization of C99 polypeptides in relation to PS1. HEK293 cells were co-transfected with vectors encoding PS1 and either C99(KKQN) (A) or C99(QLQN) (B). The distribution of PS1 was determined with a rabbit polyclonal antibody against the N-terminal portion of PS1, followed by Texas Red-conjugated goat anti-rabbit IgG. C99 was visualized with the 9E10 anti-Myc monoclonal antibody, followed by FITC-conjugated goat anti-mouse IgG. Staining of endogenous PS1 in the non-transfected cells was below the threshold of detection at the exposure times used for the photographs.

Retention of C99 in the ER Affects the Biogenesis of Both Abeta 40 and Abeta 42-- Because the immunoblot methods used in the preceding studies did not distinguish between long and short forms of Abeta , it was conceivable that retention of C99 in the ER selectively prevented the production of the more abundant Abeta 40, while having little or no effect on the formation of smaller amounts of Abeta 42. To examine this possibility, the comparative studies of C99(QLQN) and C99(KKQN) were repeated in 293 cells, using specific and highly sensitive ELISAs to quantify Abeta 40 and Abeta 42 (Fig. 7). The concentration of Abeta 40 fell by ~98% in the cultures expressing C99 with the ER retention motif, in accord with the major loss of Abeta signal in the earlier immunoblot studies. In addition, these studies clearly revealed that the concentration of the less abundant Abeta 42 underwent a parallel 96% decline in the same cultures. It should be noted that the reporter antibody used in these assays (6H9) is specific for the region of Abeta distal to the alpha -secretase cleavage site. Thus, the results indicate that retention of C99 in the ER caused a decline in all potential gamma -secretase products, including any N-terminal "ragged" forms of Abeta that could arise from beta -secretase cleavage at alternative sites (88), as well as any p3 peptides formed from gamma -secretase cleavage of C83 fragments remaining after alpha -secretase cleavage of endogenous APP in the transfected cells.


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 7.   Addition of ER retention signal to C99 causes a similar reduction of both Abeta 40 and Abeta 42. HEK293 cells were transfected with vectors encoding C99(QLQN) or C99(KKQN), and equal aliquots of conditioned medium were subjected to ELISA to determine the concentrations of Abeta 40 and Abeta 42. Each value is a mean (± S.E.) from assays performed on three parallel cultures.

Co-expression of C99 with a Dominant-negative Rab1B GTPase Inhibits Abeta Production-- Although the preceding studies strongly suggested that reduced Abeta formation in cells expressing C99(KKQN) was due to retention of the gamma -secretase substrate in the ER, we could not rule out the alternative possibility that the introduction of the two lysine residues at the C terminus of the polypeptide, and its consequent association with the COP-I coatomer complex, might somehow interfere with the recognition of C99 by gamma -secretase. To address this issue, we used a different approach to retain C99 in the ER. This entailed co-expressing C99 with either wild-type Rab1B or a dominant-negative Rab1B mutant, i.e. Rab1B(N121I). Previous studies have established that the Rab1 GTPase functions as a molecular switch in the ER right-arrow Golgi transport pathway (89, 90). Introduction of the amino acid substitution, N121I, into Rab1B drastically reduces its affinity for GTP and renders the protein a dominant suppressor of protein trafficking between the ER and Golgi compartments (58, 91).

Immunofluorescence analysis confirmed that Rab1B(N121I) had the predicted effect on C99 localization (Fig. 8). That is when C99(QLQN) was co-expressed with Myc-tagged Rab1B(N121I), it assumed a diffuse reticular staining pattern similar to that previously observed for C99(KKQN) (see Fig. 5). On the other hand, when C99 (QLQN) was co-expressed with wild-type Rab1B, it accumulated mainly in the juxtanuclear Golgi region (Fig. 8).


View larger version (32K):
[in this window]
[in a new window]
 
Fig. 8.   Effects of Rab1B(N121I) on the intracellular localization of C99(QLQN). Cells were fixed 24 h after being co-transfected with expression vectors encoding C99(QLQN) and either Rab1B(wt) or Rab1B(N121I), as indicated. The localization of C99 was determined with the 13G8 mouse monoclonal antibody, followed by Texas Red-conjugated goat anti-mouse IgG (red). The ER was highlighted with an affinity-purified rabbit polyclonal antibody against calreticulin, followed by FITC-conjugated goat anti-rabbit IgG (green). At the exposure times used for the photographs, staining of endogenous APP with the 13G8 antibody in the non-transfected cells was below the threshold of detection.

We next examined the effect of the dominant-negative Rab1B(N121I) on Abeta production in 293 cells. Because Rab mutants that fail to bind guanine nucleotides are unstable, they do not accumulate to the same extent as their wild-type counterparts when transiently expressed in cultured cells. This is evident in Fig. 9A, where the upper band, representing the Myc-tagged Rab1B(N121I) was expressed approximately 2-fold over endogenous Rab1B, compared with an approximate 10-fold overexpression for Myc-Rab1B(wt). However, it is important to note that the transfection efficiency in this study is ~15-20%. Thus, the 2:1 ratio of Myc-Rab1B(N121I) versus endogenous Rab1B in the total cell lysate reflects a 10:1 ratio in the subpopulation of transfected cells. Our previous studies have clearly established that this level of Rab1B(N121I) overexpression completely blocks ER right-arrow Golgi trafficking of the low density lipoprotein receptor (63) and APP (58). As shown in Fig. 9C, co-expression of C99(QLQN) with the Rab1B(N121I) caused a 90% reduction in extracellular Abeta , compared with cells expressing the same C99 construct with Rab1B(wt). As determined previously for cells expressing C99 with the di-lysine retention motif, the decline in extracellular Abeta caused by co-expression of C99(QLQN) with Rab1B(N121I) was matched by a similar reduction of Abeta in the cell lysates (not shown), indicating that it was not due to intracellular sequestration of the peptide. Furthermore, the reduction in Abeta seen in the cells expressing the dominant-negative Rab1B mutant could not be explained by an inhibitory effect of Rab1B(N121I) on overall expression of the C99(QLQN) substrate, which showed similar steady-state levels in cells expressing either the wt or N121I Rab1B constructs (Fig. 9B). In this regard, it might at first seem puzzling that intracellular levels of the C99 substrate did not increase noticeably in conjunction with the block in Abeta production caused by the Rab1B mutant. However, this was not entirely unexpected since, under conditions of continuous C99 overexpression, the fractional conversion of C99 to Abeta is actually much lower than is suggested by direct comparison of the blots shown in Fig. 9, B and C. The Abeta blots shown in Fig. 9C were subjected to a special high sensitivity detection method involving biotinylated IgG and streptavidin-horseradish peroxidase. Under the standard ECL conditions and exposure times used for C99 (Fig. 9B), Abeta was almost undetectable. It is also important to mention that other proteases besides gamma -secretase probably contribute to the turnover of C99. For example, recent studies (92, 93) have documented the existence of calpain-like proteases that can degrade C99 in the ER. It is possible that these enzymes may assume a greater role in C99 degradation when the protein is prevented from exiting the ER in cells expressing Rab1B(N121I).


View larger version (54K):
[in this window]
[in a new window]
 
Fig. 9.   Retention of C99(QLQN) in the ER by co-expression with a dominant-negative Rab1B mutant inhibits Abeta production but does not block the cleavage of PS1 or SREBP2. HEK293 cells were co-transfected with vectors encoding C99(QLQN) and either Rab1B(wt) or Rab1B(N121I). A and B, expression of the recombinant proteins was verified by SDS-PAGE and immunoblot analysis of equal aliquots of cell lysate using polyclonal antibody against Rab1B (A) or 6E10 antibody to detect C99 (B). A, the recombinant Rab1B is distinguished from the endogenous protein by its slightly slower mobility, which is due to the presence of an N-terminal Myc epitope tag (arrows). C, equal aliquots of medium from the same cultures were subjected to electrophoresis and immunoblot analysis to detect Abeta as described under "Experimental Procedures." The blots shown in the illustration are representative of determinations performed on three parallel cultures. The Abeta values in the culture expressing Rab1B(N121I) were reduced to 8.5 ± 1.9 (S.E.) percent of the values in the cultures expressing Rab1B(wt). D shows an immunoblot performed with an antibody against the N terminus of PS1 in 293 cells where PS1 was co-expressed with either Rab1B(wt) or Rab1B(N121I), as indicated. The full-length PS1 (FL) and N-terminal fragments (NTF) are indicated to the right of the panel. Material above 50 kDa represents PS1 aggregates typically seen on SDS gels. The lane on the right contains lysate from 293 cells transfected only with the Rab1B(N121I) construct. Expression levels of the wild-type and N121I Rab1B constructs (not shown) were similar to those in A. E shows immunoblots of membrane and nuclear fractions from sterol-deprived 293 cells co-expressing HSV-tagged SREBP2 with either Rab1B(wt) or Rab1B(N121I). Relative expression levels of the wild-type and N121I Rab1B constructs (not shown) were similar to those in A. Full-length SREBP2 and the N-terminal fragment (NTF) detected by the anti-HSV antibody are indicated by the arrows. Other bands detected by the anti-HSV antibody are nonspecific, as indicated by their presence in non-transfected 293 cells (control). Scanning of the blots indicated that ratio of nuclear NTF to full-length SREBP in the cells expressing Rab1B(N121I) was ~62% of the ratio determined in the cells expressing Rab1B(wt). Similar results were obtained in two separate experiments.

To verify that the reduced gamma -secretase cleavage of C99 in the preceding studies was related specifically to the inability of cells expressing Rab1B(N121I) to transport the substrate protein from the ER to the Golgi compartment, we carried out several follow-up studies to rule out a global perturbation of membrane-associated proteases or general disruption of cell function.

First, we asked whether or not the dominant-negative Rab1B mutant would similarly impair the endoproteolytic cleavage of presenilin-1 (PS1). In contrast to the striking reduction of Abeta production (Fig. 9C), we observed no difference in the production of PS1 N-terminal fragments when PS1 was co-expressed with either Rab1B(wt) or Rab1B(N121I) in 293 cells (Fig. 9D).

Second, we examined the effect of the dominant-negative Rab1B(N121I) on the proteolytic cleavage of a membrane protein unrelated to APP, i.e. SREBP2. The latter is localized in the ER, where sterol depletion triggers the release of the N-terminal transcriptional regulatory domain through the action of two sequential site-specific endoproteases, the second of which cleaves within a transmembrane region (94). As shown in Fig. 9E, co-expression of SREBP2 with Rab1B(N121I) did not have a major effect on the release of the N-terminal domain, which is typically found in the nuclear compartment (75). Since the cleavage of SREBP2 depends on the sequential action of two endoproteases, as well as an interaction with a sterol-sensing activating protein (95), these results strongly suggest that the block of ER right-arrow Golgi transport by the Rab1B mutant does not cause a global disruption of protein function in the ER.

Finally, to explore further the possibility of general cell damage, we performed an experiment to determine if the suppression of Abeta production by the dominant-negative Rab1B(N121I) was reversible. The cDNAs encoding Rab1B wt and N121I were subcloned into the pTRE vector, where gene expression is controlled by the Tet operator. Each of these constructs was then transfected together with pCMV-C99(QLQN) into a 293 cell line (Tet-OffTM) where the stably expressed tetracycline-controlled transactivator complex (tTA) strongly represses transcription in the presence of doxycycline. When the transfected cells were maintained in the absence of doxycycline for 24 h, Rab1B(wt) and Rab1B(N121I) were transiently expressed at levels comparable to those previously seen with unregulated cytomegalovirus vectors (Fig. 10, A and B). Also, as expected, the dominant-negative mutant completely blocked Abeta production during this period (Fig. 10C). When expression of the Rab1B constructs was subsequently suppressed by addition of doxycycline to the medium, Myc-Rab1B(N121I) declined to an undetectable level within 24 h (Fig. 10B), whereas the more stable Myc-Rab1B(wt) declined more slowly (Fig. 10A). Of particular importance, Fig. 10C shows that, in parallel with the disappearance of Rab1B(N121I), the production of Abeta was restored to levels comparable to those detected in cultures expressing Myc-Rab1B(wt) or no exogenous Rab (control with doxycycline always present).


View larger version (38K):
[in this window]
[in a new window]
 
Fig. 10.   Effects of the dominant-negative Rab1B(N121I) on Abeta production are reversible. Parallel cultures HEK293 Tet-offTM cells were co-transfected with pCMV5-C99(QLQN) and either pTRE-Rab1B(wt) (A) or pTRE-Rab1B(N121I) (B). All cultures were grown without doxycycline (-dox) for the initial 24 h after transfection to allow expression of the Rab1B proteins. At this point one set of cultures was harvested for immunoblot analysis to determine the expression levels of Myc-Rab1B relative to endogenous Rab1B (upper panel) and the expression of C99(QLQN) (lower panel), as described under "Experimental Procedures." The remaining cultures were changed to medium containing 1 µg/ml doxycycline (+dox) and harvested for immunoblot analysis at the indicated times (times are total hours after transfection). C, equal aliquots of medium (conditioned for 24-h) were removed from the cultures analyzed in A and B and subjected to immunoblot analysis. Abeta was detected as described under "Experimental Procedures," and the results were expressed as percent of the Abeta values determined for matched control cultures where doxycycline was added prior to transfection to suppress the expression of the Rab1B constructs throughout the entire 72-h post-transfection period.

Effects of PS1 Mutations on Abeta Production from C99-- Several studies have shown that co-expression of APP with mutant forms of PS1 can cause an increase in cellular production of Abeta 42 versus Abeta 40 (38, 39, 64, 96). This implies that interactions between APP and presenilins play a critical role in determining the exact site where gamma -secretase cuts the polypeptide chain at the C-terminal end of the Abeta sequence. Although it is generally assumed that APP is cleaved by gamma -secretase after the N-terminal exodomain is removed by either alpha -secretase or beta -secretase, it remains unclear whether or not the exodomain of APP is involved in the initial protein interactions with gamma -secretase/PS1. By using our C99 construct, we have been able to explore this issue by co-expressing C99 with wild-type or mutant forms of PS1 in 293 cells and then determining the concentrations of Abeta 40 and Abeta 42 in the conditioned culture medium. Immunoblot analysis of PS1 in the transfected cells indicated that the wild-type and mutant forms of the protein were very similar with respect to overall expression and the extent of endoproteolytic cleavage (Fig. 11A). Quantification of long and short forms of Abeta in these cells revealed a striking 90% increase in the ratio of Abeta 42 to Abeta 40 when C99 was co-expressed with either PS1(M146L) or PS1(L286V), compared with cells co-expressing C99 with PS1wt (Fig. 11B). This increase was comparable to that previously observed when the same PS1 mutants were co-expressed with full-length SwAPP (64). Based on this finding, it appears that the exodomain of APP is not required for the elevation of the Abeta 42/Abeta 40 ratio by the PS1 mutants.


View larger version (39K):
[in this window]
[in a new window]
 
Fig. 11.   Mutant forms of PS1 increase the production of Abeta 42 versus Abeta 40 from C99. HEK 293 cells were co-transfected with the vector encoding C99(QLQN) combined with vectors encoding either PS1(wt), PS1(M146L), or PS1(L286V) as indicated. Cells and medium were collected 24 h after transfection. A, immunoblot assays were performed on aliquots of the cell lysates to confirm that comparable levels of C99 and PS1 expression were obtained in all of the cultures. The major PS1 bands at ~23 and 45 kDa represent the N-terminal fragment and the full-length protein, respectively. Endogenous PS1 was not detectable at the exposure times used for these blots (not shown). The blots shown in the illustration are representative of determinations performed on three parallel cultures. B, equal aliquots of medium from the same cultures were subjected to ELISA to quantify Abeta 42 and Abeta 40, as described under "Experimental Procedures." Each bar shows the mean ± S.E. of separate determinations from three parallel cultures.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

gamma -Secretase catalyzes the terminal step in the proteolytic processing of APP, leading to the release of Abeta . The subcellular localization of gamma -secretase remains uncertain, although a few reports have implied that this activity may exist in early compartments of the secretory pathway (46-48). The first part of this study was designed to test the hypothesis that one or more gamma -secretase activities reside in the ER. We began by adding a di-lysine ER retention motif to SwAPP. Retention of this protein in the ER was clearly demonstrated by 1) the impairment of Golgi-dependent post-translational modifications and 2) reduction of exodomain products normally released after SwAPP is cut by alpha -secretase or beta -secretase in medial or late compartments of the secretory pathway. These results confirm previous reports (26, 28, 50, 97) indicating that most of the beta -secretase activity resides in subcellular compartments distal to the ER. Moreover, they suggest that the recently described maturation and cleavage of the beta -secretase pro-peptide after it leaves the ER (98) may be required for activation of the enzyme.

In the cells expressing SwAPP(KKQN), the amounts of both Abeta 40 and Abeta 42 released into the medium were markedly reduced. Because the full-length SwAPP(KKQN) construct was unable to progress beyond the first step in the amyloidogenic pathway (i.e. the translocation of APP to sites containing active beta -secretase), its utility for assessing gamma -secretase localization was limited. To circumvent this problem and obtain a direct measure of gamma -secretase activity, we generated a C99 construct, C99(QLQN) which represents the C-terminal stump of APP that remains after beta -secretase cleavage, with a C-terminal Myc epitope and a tetrapeptide extension similar to the normal APP C-terminal sequence, QMQN. Our initial studies showed that this construct was a good physiological substrate for gamma -secretase, giving rise to abundant amounts of Abeta 40 and Abeta 42 that could be easily detected with several different antibodies directed against epitopes at the N terminus and C terminus of the peptide. When the di-lysine motif, KKQN, was added to C99, retention of the protein in the ER was indicated by a marked change in its immunofluorescence localization from a predominant Golgi-like pattern to one that closely matched the ER marker, calreticulin.

Measurements of Abeta in the medium from cells expressing C99(KKQN) revealed a near-complete block in deposition of both Abeta 40 and Abeta 42 compared with cells expressing C99(QLQN). If the decline in extracellular Abeta was due to block in peptide secretion, we would have expected to see an increase in the intracellular Abeta pool accompanying the decreased peptide output. Instead, we observed a corresponding decrease in intracellular Abeta , strongly suggesting that the ER retention signal was preventing biogenesis of the peptide. To confirm that the reduced Abeta production was specifically related to retention of C99 in the ER, rather than to the di-lysine motif interfering with gamma -secretase substrate interactions, we retained C99 in the ER without the di-lysine signal by co-expressing it with a dominant-negative Rab1B mutant that blocks ER right-arrow Golgi trafficking (58, 63). These studies showed that C99(QLQN), which normally gave rise to substantial amounts of Abeta when expressed in 293 cells, was unable to generate Abeta when its transport out of the ER was blocked. The latter effect was readily reversed when expression of the Rab1B mutant was suppressed, and the functions of other ER endoproteases operating on PS1 and SREBP2 were not disrupted. Taken together, these observations lead us to conclude that the ER is not a major site for gamma -secretase processing of the APP C99 fragment in the well characterized 293 cell model. Our results contrast with those of Soriano et al. (48), who found no reduction of Abeta 40 or Abeta 42 secretion in Chinese hamster ovary cells expressing an APP/CD3gamma chimera that was retained in the ER. At present we cannot offer a simple explanation for these conflicting results. One possibility is that major cell type-specific differences exist in the distribution of gamma -secretase. However, the marked reduction of Abeta that we observed when C99(KKQN) was expressed in NT2N neurons indicates that these cells are similar to 293 cells insofar as most of the gamma -secretase activity appears to exist outside of the ER.

It has been proposed that Abeta 40 and Abeta 42 are generated by different gamma -secretases (16, 17), with the enzyme responsible for producing the long form of Abeta residing in the ER and the enzyme producing Abeta 40 localized mainly in the endosomes or other peripheral compartments (52). Although the present study does not directly rule out the existence of multiple gamma -secretases that cut C99 at different sites, the parallel reductions in the amounts of Abeta 40 and Abeta 42 produced by 293 cells expressing C99(KKQN) argue against the idea that a different gamma -secretase responsible for generating Abeta 42 versus Abeta 40 is selectively compartmentalized in the ER. It remains to be determined precisely where, beyond the ER, the final step in Abeta biogenesis actually occurs and how the peptide is released from the cell. Under normal circumstances it is difficult to detect substantial amounts of C99 or C83 in cultured cells, suggesting that these intermediate fragments are rapidly cleaved by gamma -secretase. However, in cells transfected with the C99 plasmids, overexpression of the substrate appears to saturate the endogenous gamma -secretase processing pathway, with consequent accumulation of a large C99 pool that can be readily detected by immunoblot analysis. The presence of this material in the Golgi apparatus, and to a lesser extent in the endosomes, could indicate that these are normal sites of gamma -secretase processing. This would be consistent with numerous studies pointing to the involvement of acidic compartments in Abeta biogenesis (6, 30, 31, 99).

The apparent absence of substantial gamma -secretase activity in the ER has important implications for understanding the relationship between presenilins and APP processing. Mutations in PS1 (100) and PS2 (101) have been linked to early-onset familial forms of Alzheimer's disease, with the majority of the known mutations occurring in PS1 (102, 103). Several of the amino acid substitutions in the presenilins have been shown to cause alterations in the amyloidogenic processing of APP, such that cells produce an increased amount of Abeta 42 relative to Abeta 40 (36-39, 104). The molecular mechanism underlying this effect remains controversial. Presenilins are serpentine polypeptides with multiple hydrophobic membrane-spanning segments and a large cytoplasmic loop (105, 106), and there is some evidence for a direct physical interaction between PS1 and APP, based on co-immunoprecipitation studies (107). Both endogenous and overexpressed presenilins are localized predominantly in the perinuclear region and the ER (49-51, 108, 109). Nascent presenilins undergo endoproteolytic cleavage in vivo to produce stable N-terminal and C-terminal derivatives (87, 110, 111). This "presenilinase" activity is completely abolished by substitutions of two conserved aspartate residues that lie in the transmembrane domains flanking the cleavage site (40, 41). Interestingly, the same studies show that the aspartate substitutions in presenilin also reduce gamma -secretase activity in cell lysates, raising the prospect that presenilins are autoactivated aspartyl proteases that function as gamma -secretases. Further support for this hypothesis comes from recent studies in which photoactivated gamma -secretase inhibitors have been shown to bind directly to the cleaved forms of PS1 and PS2 (42, 43). If PS1 and gamma -secretase are truly the same molecule, then one might expect to observe an increase in Abeta production in cells where the C99 substrate is retained in the ER where most of the PS1 resides, compared with cells where C99 is exported to other compartments. In fact, our studies show the exact opposite, with Abeta production being almost completely abolished in cells where C99 was retained in the ER by inclusion of the di-lysine motif or disruption of ER right-arrow Golgi trafficking with a Rab1B mutant. One interpretation of these findings is that most of the intracellular PS1 residing in the ER is catalytically inactive as gamma -secretase, whereas a small pool of PS1 is converted to a functional gamma -secretase in one or more peripheral cellular compartments. This conversion could involve a conformational change in the PS1 sub-domains or an unmasking of cleavage sites in the APP substrate, perhaps related to the assembly of these proteins into a large multimeric complex such as that described by Li et al. (112) and/or interaction with accessory proteins such as nicastrin (57). A similar model has been invoked to explain why PS1 (gamma -secretase) cleaves the C-terminal domain of Notch at the plasma membrane, even though PS1 apparently can bind to Notch in the ER and Golgi compartments (113). In the latter case, activation of the proteolytic cleavage may be related to a ligand-induced conformational change in the Notch substrate that changes the nature of the PS1/Notch interaction.

Regardless of whether the presenilins function as gamma -secretases by themselves or as part of a larger protein complex, the present studies clearly show that mutant versions of PS1 can affect the biogenesis of Abeta when expressed with only the C99 stump of APP. Specifically, the increase in Abeta 42/Abeta 40 seen when C99 was co-expressed with PS1 L286V or M146I was similar in magnitude to that previously reported when the same mutants were expressed with full-length SwAPP (64). This demonstrates that the exodomain of APP is not required for the relevant PS1 interactions. When combined with earlier observations indicating that the association of PS1 with APP can occur in the absence of the APP cytoplasmic tail (107), our results suggest that the critical domain for interaction with PS1 may be confined to a narrow region of APP that lies between the beta -secretase cleavage site and the end of the transmembrane domain. This conclusion is consistent with the mutagenesis studies of Lichtenthaler et al. (114), which indicate that the cleavage specificity of gamma -secretase (resulting in Abeta 40 or Abeta 42) is determined largely by the eight amino acid residues immediately downstream of the cleavage site within the transmembrane region of C99. Thus, it is likely that modified C99 constructs will be particularly useful in future studies aimed at defining the specific structural domains involved in the physical interactions between PS1 and the transmembrane region of APP.

    FOOTNOTES

* This work was supported by National Institutes of Health Grant RO1-AG16166 (to W. A. M.)The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ To whom correspondence should be addressed: Dept. of Biochemistry and Molecular Biology, Medical College of Ohio, 3035 Arlington Ave., Toledo, OH 43614. Tel.: 419-383-4100; Fax: 419-383-6228; E-mail: wmaltese@mco.edu.

Published, JBC Papers in Press, March 7, 2001, DOI 10.1074/jbc.M007238200

    ABBREVIATIONS

The abbreviations used are: Abeta , amyloid beta -peptide; APP, amyloid precursor protein; ER, endoplasmic reticulum; PS, presenilin; FAD, familial Alzheimer's disease; DMEM, Dulbecco's modified Eagle medium; FBS, fetal bovine serum; PCR, polymerase chain reaction; PAGE, polyacrylamide gel electrophoresis; ECL, enhanced chemiluminescence; ELISA, enzyme-linked immunosorbent assay; SREBP, sterol regulatory element-binding protein; FITC, fluorescein isothiocyanate; HSV, herpes simplex virus; wt, wild type; Tricine, N-[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]glycine; PBS, phosphate-buffered saline.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Haass, C., Schlossmacher, M. G., Hung, A. Y., Vigo-Pelfrey, C., Mellon, A., Ostaszewski, B. L., Lieberburg, I., Koo, E. H., Schenk, D., Teplow, D. B., and Selkoe, D. J. (1992) Nature 359, 322-325[CrossRef][Medline] [Order article via Infotrieve]
2. Golde, T. E., Estus, S., Younkin, L. H., Selkoe, D. J., and Younkin, S. G. (1992) Science 255, 728-730[Medline] [Order article via Infotrieve]
3. Gandy, S., and Greengard, P. (1994) Int. Rev. Neurobiol. 30, 29-50
4. Sisodia, S. S., and Price, D. L. (1995) FASEB J. 9, 366-370[Abstract/Free Full Text]
5. Haass, C., and Selkoe, D. J. (1993) Cell 75, 1039-1042[Medline] [Order article via Infotrieve]
6. Haass, C., Hung, A. Y., Schlossmacher, M. G., Teplow, D. B., and Selkoe, D. J. (1993) J. Biol. Chem. 268, 3021-3024[Abstract/Free Full Text]
7. Esch, F. S., Keim, P. S., Beattie, E. C., Blacher, R. W., Culwell, A. R., Oltersdorf, T., McClure, D., and Ward, P. J. (1990) Science 248, 1122-1124[Medline] [Order article via Infotrieve]
8. Ramabhadran, T. V., Gandy, S. E., Ghiso, J., Czernik, A. J., Ferris, D., Bhasin, R., Goldgaber, D., Frangione, B., and Greengard, P. (1993) J. Biol. Chem. 268, 2009-2012[Abstract/Free Full Text]
9. DeStrooper, B., Umans, L., Van Leuven, F., and Van Den Berghe, H. (1993) J. Cell Biol. 121, 295-304[Abstract]
10. Zhong, Z., Higaki, J., Murakami, K., Wang, Y., Catalano, R., Quon, D., and Cordell, B. (1994) J. Biol. Chem. 269, 627-632[Abstract/Free Full Text]
11. Murphy, M. P., Hickman, L. J., Eckman, C. B., Uljon, S. N., Wang, R., and Golde, T. E. (1999) J. Biol. Chem. 274, 11914-11923[Abstract/Free Full Text]
12. Tischer, E., and Cordell, B. (1996) J. Biol. Chem. 271, 21914-21919[Abstract/Free Full Text]
13. Coles, M., Bicknell, W., Watson, A. A., Fairlie, D. P., and Craik, D. J. (1998) Biochemistry 37, 11064-11077[CrossRef][Medline] [Order article via Infotrieve]
14. Shoji, M., Golde, T. E., Ghiso, J., Cheung, T. T., Estus, S., Shaffer, L. M., Cai, X. D., McKay, D. M., Tintner, R., Frangione, B., and Younkin, S. G. (1992) Science 258, 126-129[Medline] [Order article via Infotrieve]
15. Seubert, P., Oltersdorf, T., Lee, M. G., Barbour, R., Blomquist, C., Davis, D. L., Bryant, K., Fritz, L. C., Galasko, D., Thai, L. J., Leiberburg, I., and Schenk, D. B. (1993) Nature 361, 260-263[CrossRef][Medline] [Order article via Infotrieve]
16. Citron, M., Diehl, T. S., Gordon, G., Biere, A. L., Seubert, P., and Selkoe, D. J. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 13170-13175[Abstract/Free Full Text]
17. Klafki, H.-W., Abramowski, R., Swoboda, R., Paganetti, P. A., and Staufenbiel, M. (1996) J. Biol. Chem. 271, 28655-28659[Abstract/Free Full Text]
18. Durkin, J. T., Murthy, S., Husten, E. J., Trusko, S. P., Savage, M. J., Rotella, D. P., Greenberg, B. D., and Siman, R. (1999) J. Biol. Chem. 274, 20499-20504[Abstract/Free Full Text]
19. Gravina, S. A., Ho, L., Eckman, C. B., Long, K. E., Otvos Jr, L., Younkin, L. H., Suzuki, N., and Younkin, S. G. (1995) J. Biol. Chem. 270, 7013-7016[Abstract/Free Full Text]
20. Roher, A. E., Lowenson, J. D., Clarke, S., Woods, A. S., Cotter, R. J., Gowing, E., and Ball, M. J. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 10836-10840[Abstract]
21. Iwatsubo, T., Odaka, A., Suzuki, N., Mizusawa, H., Nukina, N., and Ihara, Y. (1995) Neuron 13, 45-53
22. Roberts, S. B., Ripellino, J. A., Ingalls, K. M., Nikolaos, N. K., and Felsenstein, K. M. (1994) J. Biol. Chem. 269, 3111-3116[Abstract/Free Full Text]
23. Lammich, S., Kojro, E., Postina, R., Gilbert, S., Pfeiffer, R., Jasionowski, M., Haass, C., and Fahrenholz, F. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 3922-3927[Abstract/Free Full Text]
24. Sisodia, S. S. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 6075-6079[Abstract]
25. Sambamurti, K., Shioi, J., Anderson, J. P., Pappolla, M. A., and Robakis, N. K. (1992) J. Neurosci. Res. 33, 319-329[Medline] [Order article via Infotrieve]
26. Haass, C., Lemere, C. A., Capell, A., Citron, M., Seubert, P., Schenk, D., Lannfelt, L., and Selkoe, D. J. (1995) Nat. Med. 1, 1291-1296[Medline] [Order article via Infotrieve]
27. McConlogue, L., Castellano, F., DeWit, C., Schenk, D., and Maltese, W. A. (1996) J. Biol. Chem. 271, 1343-1348[Abstract/Free Full Text]
28. Thinakaran, G., Teplow, D. B., Siman, R., Greenberg, B., and Sisodia, S. S. (1996) J. Biol. Chem. 271, 9390-9397[Abstract/Free Full Text]
29. Koo, E. H., and Squazzo, S. L. (1994) J. Biol. Chem. 269, 17386-17389[Abstract/Free Full Text]
30. Haass, C., Capell, A., Citron, M., Teplow, D. B., and Selkoe, D. J. (1995) J. Biol. Chem. 270, 6186-6192[Abstract/Free Full Text]
31. Knops, J., Suomensaari, S., Lee, M., McConlogue, L., Seubert, P., and Sinha, S. (1995) J. Biol. Chem. 270, 2419-2422[Abstract/Free Full Text]
32. Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Ross, S., Amarante, P., Loeloff, R., Luo, Y., Fisher, S., Fuller, J., Edenson, S., Lile, J., Jarosinski, M. A., Biere, A. L., Curran, E., Burgess, T., Louis, J. C., Collins, F., Treanor, J., Rogers, G., and Citron, M. (1999) Science 286, 735-741[Abstract/Free Full Text]
33. Sinha, S., Anderson, J. P., Barbour, R., Basi, G. S., Caccavello, R., Davis, D., Doan, M., Dovey, H. F., Frigon, N., Hong, J., Jacobson-Croak, K., Jewett, N., Keim, P., Knops, J., Lieberburg, I., Power, M., Tan, H., Tatsuno, G., Tung, J., Schenk, D., Seubert, P., Suomensaari, S. M., Wang, S., Walker, D., Zhao, J., McConlogue, L., and John, V. (1999) Nature 402, 537-540[CrossRef][Medline] [Order article via Infotrieve]
34. Hussain, I., Powell, D., Howlett, D. R., Tew, D. G., Meek, T. D., Chapman, C., Gloger, I. S., Murphy, K. E., Southan, C. D., Ryan, D. M., Smith, T. S., Simmons, D. L., Walsh, F. S., Dingwall, C., and Christie, G. (1999) Mol. Cell. Neurosci. 14, 419-427[CrossRef][Medline] [Order article via Infotrieve]
35. Yan, R., Bienkowski, M. J., Shuck, M. E., Miao, H., Tory, M. C., Pauley, A. M., Brashier, J. R., Stratman, N. C., Mathews, W. R., Buhl, A. E., Carter, D. B., Tomasselli, A. G., Parodi, L. A., Heinrikson, R. L., and Gurney, M. E. (1999) Nature 402, 533-537[CrossRef][Medline] [Order article via Infotrieve]
36. Duff, K., Eckman, C., Zehr, C., Yu, X., Prada, C.-M., Perez-tur, J., Hutton, M., Buee, L., Harigaya, Y., Yager, D., Morgan, D., Gordon, M. N., Holcomb, L., Refolo, L., Zenk, B., Hardy, J., and Younkin, S. (1996) Nature 383, 710-713[CrossRef][Medline] [Order article via Infotrieve]
37. Lemere, C. A., Lopera, F., Kosik, K. S., Lendon, C. L., Ossa, J., Saido, T. C., Yamaguchi, H., Ruiz, A., Martinez, A., Madrigal, L., Hincapie, L., Arango, J. C., Anthony, D. C., Koo, E. H., Goate, A. M., Selkoe, D. J., and Arango, J. C. (1996) Nat. Med. 2, 1146-1150[Medline] [Order article via Infotrieve]
38. Xia, W., Zhang, J., Kholodenko, D., Citron, M., Podlinsky, M., Teplow, D., Haass, C., Seubert, P., Koo, E., and Selkoe, D. (1997) J. Biol. Chem. 272, 7977-7982[Abstract/Free Full Text]
39. Tomita, T., Narytana, K., Saido, T. C., Kume, H., Shinozaki, K., Tokuhiro, S., Capell, A., Walter, J., Grunberg, J., Haass, C., Iwatsubo, T., and Obata, K. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 2025-2030[Abstract/Free Full Text]
40. Wolfe, M. S., Xia, W., Ostaszewski, B. L., Diehl, T. S., Kimberly, W. T., and Selkoe, D. J. (1999) Nature 398, 513-517[CrossRef][Medline] [Order article via Infotrieve]
41. Kimberly, W. T., Xia, W., Rahmati, T., Wolfe, M. S., and Selkoe, D. J. (2000) J. Biol. Chem. 275, 3173-3178[Abstract/Free Full Text]
42. Li, Y. M., Xu, M., Lai, M. T., Huang, Q., Castro, J. L., DiMuzio-Mower, J., Harrison, T., Lellis, C., Nadin, A., Neduvelil, J. G., Register, R. B., Sardana, M. K., Shearman, M. S., Smith, A. L., Shi, X. P., Yin, K. C., Shafer, J. A., and Gardell, S. J. (2000) Nature 405, 689-694[CrossRef][Medline] [Order article via Infotrieve]
43. Esler, W. P., Kimberly, W. T., Ostaszewski, B. L., Diehl, T. S., Moore, C. L., Tsai, J. Y., Rahmati, T., Xia, W., Selkoe, D. J., and Wolfe, M. S. (2000) Nat. Cell Biol. 2, 428-434[CrossRef][Medline] [Order article via Infotrieve]
44. Octave, J. N., Essalmani, R., Tasiaux, B., Menager, J., Czech, C., and Mercken, L. (2000) J. Biol. Chem. 275, 1525-1528[Abstract/Free Full Text]
45. Murphy, M. P., Uljon, S. N., Fraser, P. E., Fauq, A., Lookingbill, H. A., Findlay, K. A., Smith, T. E., Lewis, P. A., McLendon, D. C., Wang, R., and Golde, T. E. (2000) J. Biol. Chem. 275, 26277-26284[Abstract/Free Full Text]
46. Chyung, A. S. C., Greenberg, B. D., Cook, D. G., Doms, R. W., and Lee, V. M. (1997) J. Cell Biol. 138, 671-680[Free Full Text]
47. Wild-Bode, C., Yamazaki, T., Capell, A., Leimer, U., Steiner, H., Ihara, Y., and Haass, C. (1997) J. Biol. Chem. 272, 16085-16088[Abstract/Free Full Text]
48. Soriano, S., Chyung, A. S., Chen, X., Stokin, G. B., Lee, V. M., and Koo, E. H. (1999) J. Biol. Chem. 274, 32295-32300[Abstract/Free Full Text]
49. De Strooper, B., Beullens, M., Contreras, B., Levesque, L., Craessaerts, K., Cordell, B., Moechars, D., Bollen, M., Fraser, P., George-Hyslop, P. S., and Van Leuven, F. (1997) J. Biol. Chem. 272, 3590-3598[Abstract/Free Full Text]
50. Annaert, W. G., Levesque, L., Craessaerts, K., Dierinck, I., Snellings, G., Westaway, D., George-Hyslop, P. S., Cordell, B., Fraser, P., and De Strooper, B. (1999) J. Cell Biol. 147, 277-294[Abstract/Free Full Text]
51. Zhang, J., Kang, D. E., Xia, W., Okochi, M., Mori, H., Selkoe, D. J., and Koo, E. H. (1998) J. Biol. Chem. 273, 12436-12442[Abstract/Free Full Text]
52. Hartmann, T., Bieger, S. C., Bruhl, B., Tienari, P. J., Ida, N., Allsop, D., Roberts, G. W., Masters, C. L., Dotti, C. G., Unsicker, K., and Beyreuther, K. (1997) Nat. Med. 3, 1016-1020[Medline] [Order article via Infotrieve]
53. Lippincott-Schwartz, J., Yuan, L., Tipper, C., Amherdt, M., Orci, L., and Klausner, R. D. (1991) Cell 67, 601-616[Medline] [Order article via Infotrieve]
54. Wood, S. A., Park, J. E., and Brown, W. J. (1991) Cell 67, 591-600[Medline] [Order article via Infotrieve]
55. Lai, A., Sisodia, S. S., and Trowbridge, I. S. (1995) J. Biol. Chem. 270, 3565-3573[Abstract/Free Full Text]
56. Sastre, M., Turner, R. S., and Levy, E. (1998) J. Biol. Chem. 273, 22351-22357[Abstract/Free Full Text]
57. Yu, G., Nishimura, M., Arawaka, S., Levitan, D., Zhang, L., Tandon, A., Song, Y. Q., Rogaeva, E., Chen, F., Kawarai, T., Supala, A., Levesque, L., Yu, H., Yang, D. S., Holmes, E., Milman, P., Liang, Y., Zhang, D. M., Xu, D. H., Sato, C., Rogaev, E., Smith, M., Janus, C., Zhang, Y., Aebersold, R., Farrer, L. S., Sorbi, S., Bruni, A., Fraser, P., and George-Hyslop, P. (2000) Nature 407, 48-54[CrossRef][Medline] [Order article via Infotrieve]
58. Dugan, J. M., DeWit, C., McConlogue, L., and Maltese, W. A. (1995) J. Biol. Chem. 270, 10982-10989[Abstract/Free Full Text]
59. Mullan, M., Crawford, F., Axelman, K., Houlden, H., Lilius, L., Winblad, B., and Lannfelt, L. (1992) Nat. Genet. 1, 345-347[Medline] [Order article via Infotrieve]
60. Citron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., and Selkoe, D. J. (1992) Nature 360, 672-674[CrossRef][Medline] [Order article via Infotrieve]
61. Cai, X.-D., Golde, T. E., and Younkin, S. G. (1993) Science 259, 514-516[Medline] [Order article via Infotrieve]
62. Andersson, S., Davis, D. L., Dahlback, H., Jornvall, H., and Russell, D. W. (1989) J. Biol. Chem. 264, 8222-8229[Abstract/Free Full Text]
63. Castellano, F. C., Wilson, A. L., and Maltese, W. A. (1995) J. Recept. Signal Transduct. Res. 15, 847-862[Medline] [Order article via Infotrieve]
64. Tan, Y., Hong, J., Doan, T., McConlogue, L., and Maltese, W. A. (1998) Biochim. Biophys. Acta 1407, 69-78[Medline] [Order article via Infotrieve]
65. Pleasure, S. J., and Lee, V. M. Y. (1993) J. Neurosci. Res. 35, 585-602[Medline] [Order article via Infotrieve]
66. Sheridan, K. M., and Maltese, W. A. (1998) J. Mol. Neurosci. 10, 121-128[Medline] [Order article via Infotrieve]
67. Frolov, I., Hoffman, T. A., Pragai, B. M., Dryga, S. A., Huang, H. V., Schlesinger, S., and Rice, C. M. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 11371-11377[Abstract/Free Full Text]
68. Piper, R. C., Slot, J. W., Li, G., Stahl, P. D., and James, D. E. (1994) Methods Cell Biol. 43, 55-78[Medline] [Order article via Infotrieve]
69. Maltese, W. A., Sheridan, K. M., Repko, E. M., and Erdman, R. A. (1990) J. Biol. Chem. 265, 2148-2155[Abstract/Free Full Text]
70. Games, D., Adams, D., Alessandrini, R., Barbour, R., Berthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., Guido, T., Hagoplan, S., Johnson-Wood, K., Khan, K., Lee, M., Leibowitz, P., Lieberburg, I., Little, S., Masliah, E., McConlogue, L., Montoya-Zavala, M., Mucke, L., Paganini, L., Penniman, E., Power, M., Schenk, D., Seubert, P., Snyder, B., Soriano, F., Tan, H., Vitale, J., Wadsworth, S., Wolozin, B., and Zhao, J. (1995) Nature 373, 523-527[CrossRef][Medline] [Order article via Infotrieve]
71. Li, J., Xu, M., Zhou, H., Ma, J., and Potter, H. (1997) Cell 90, 917-927[Medline] [Order article via Infotrieve]
72. Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, M., Davis, D., Sinha, S., Schlossmacher, M., Whaley, J., Swindlehurst, C., McCormack, R., Wolfert, R., Selkoe, D., Lieberburg, I., and Schenk, D. (1992) Nature 359, 325-327[CrossRef][Medline] [Order article via Infotrieve]
73. Cha, Y., Holland, S. M., and August, J. T. (1990) J. Biol. Chem. 265, 5008-5013[Abstract/Free Full Text]
74. Hua, X., Sakai, J., Ho, Y. K., Goldstein, J. L., and Brown, M. S. (1995) J. Biol. Chem. 270, 29422-29427[Abstract/Free Full Text]
75. Hua, X., Sakai, J., Brown, M. S., and Goldstein, J. L. (1996) J. Biol. Chem. 271, 10379-10384[Abstract/Free Full Text]
76. Vincent, M. J., Martin, A. S., and Compans, R. W. (1998) J. Biol. Chem. 273, 950-956[Abstract/Free Full Text]
77. Andersson, H., Kappeler, F., and Hauri, H.-P. (1999) J. Biol. Chem. 274, 15080-15084[Abstract/Free Full Text]
78. Lotti, L. V., Mottola, G., Torrisi, M. R., and Bonatti, S. (2000) J. Biol. Chem. 274, 10413-10420[Abstract/Free Full Text]
79. Oltersdorf, T., Ward, P. J., Henricksson, T., Beattie, E. C., Neve, I. L., Lieberburg, I., and Fritz, L. C. (1990) J. Biol. Chem. 265, 4492-4497[Abstract/Free Full Text]
80. Weidemann, A., Konig, G., Bunke, D., Fischer, P., Salbaum, J. M., Masters, C. L., and Beyreuther, K. (1989) Cell 57, 115-126[Medline] [Order article via Infotrieve]
81. Kornfeld, R., and Kornfeld, S. (1985) Annu. Rev. Biochem. 54, 631-664[CrossRef][Medline] [Order article via Infotrieve]
82. Harter, C., and Wieland, F. T. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 11649-11654[Abstract/Free Full Text]
83. Wada, I., Kai, M., Imai, S., Sakane, F., and Kanoh, H. (1997) EMBO J. 16, 5420-5432[Abstract/Free Full Text]
84. Antony, C., Cibert, C., Geraud, G., Santa Maria, A., Maro, B., Mayau, V., and Goud, B. (1992) J. Cell Sci. 103, 785-796[Abstract/Free Full Text]
85. Martinez, O., Schmidt, A., Salamero, J., Hoflack, B., Roa, M., and Goud, B. (1994) J. Cell Biol. 127, 1575-1588[Abstract]
86. Mattson, M. P., and Guo, Q. (1997) J. Neurosci. Res. 50, 505-513[CrossRef][Medline] [Order article via Infotrieve]
87. Ratovitski, T., Slunt, H. H., Thinakaran, G., Price, D. L., Sisodia, S. S., and Borchelt, D. R. (1997) J. Biol. Chem. 272, 24536-24541[Abstract/Free Full Text]
88. Haass, C., Hung, A. Y., Selkoe, D. J., and Teplow, D. B. (1994) J. Biol. Chem. 269, 17741-17748[Abstract/Free Full Text]
89. Nuoffer, C., Davidson, H. W., Matteson, J., Meinkoth, J., and Balch, W. E. (1994) J. Cell Biol. 125, 225-237[Abstract]
90. Tisdale, E. J., Bourne, J. R., Khosravi-Far, R., Der, C. J., and Balch, W. E. (1992) J. Cell Biol. 119, 749-761[Abstract]
91. Peter, F., Nuoffer, C., Pind, S. N., and Balch, W. E. (1994) J. Cell Biol. 126, 1393-1406[Abstract]
92. Bunnell, W. L., Pham, H. V., and Glabe, C. G. (1998) J. Biol. Chem. 273, 31947-31955[Abstract/Free Full Text]
93. Zhang, L., Song, L., and Parker, E. M. (1999) J. Biol. Chem. 274, 8966-8972[Abstract/Free Full Text]
94. Brown, M. S., and Goldstein, J. L. (1997) Cell 89, 331-340[Medline] [Order article via Infotrieve]
95. Sakai, J., Nohturfft, A., Goldstein, J. L., and Brown, M. S. (1998) J. Biol. Chem. 273, 5785-5793[Abstract/Free Full Text]
96. Borchelt, D., Thinakaran, G., Eckman, C. B., Lee, M. K., Davenport, F., Ratovitsky, T., Prada, C. M., Kim, G., Seekins, S., Yager, D., Slunt, H. H., Wang, R., Seeger, M., Levey, A. I., Gandy, S. E., Copeland, N. G., Jenkins, N. A., Price, D. L., Younkin, S. G., and Sisodia, S. S. (1996) Neuron 17, 1005-1013[Medline] [Order article via Infotrieve]
97. Higaki, J., Quon, D., Zhong, Z., and Cordell, B. (1995) Neuron 14, 651-659[Medline] [Order article via Infotrieve]
98. Capell, A., Steiner, H., Willem, M., Kaiser, H., Meyer, C., Walter, J., Lammich, S., Multhaup, G., and Haass, C. (2000) J. Biol. Chem. 275, 30849-30854[Abstract/Free Full Text]
99. Siman, R., Mistretta, S., Durkin, J. T., Savage, M. J., Loh, T., Trusko, S., and Scott, R. W. (1993) J. Biol. Chem. 268, 16602-16609[Abstract/Free Full Text]
100. Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., Tsuda, T., Mar, L., Foncin, J. F., Bruni, A. C., Montesi, M. P., Sorbi, S., Rainero, I., Pinessi, L., Nee, L., Chumakov, I., Pollen, D., Brookes, A., Sanseau, P., Polinsky, R. J., Wasco, W., DaSilva, H. A. R., Haines, J. L., Pericak-Vance, M. A., Tanzi, R. E., Roses, A. D., Fraser, P. E., Rommens, J. M., and St. George-Hyslop, P. H. (1995) Nature 375, 754-760[CrossRef][Medline] [Order article via Infotrieve]
101. Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., Yu, C., Jondro, P. D., Schmidt, S. D., Wang, K., Crowley, A., Fu, Y.-H., Guenette, S. Y., Galas, D., Nemens, E., Wijsman, E. M., Bird, T. D., Schellenberg, G. D., and Tanzi, R. E. (1995) Science 269, 973-977[Medline] [Order article via Infotrieve]
102. Cruts, M., Hendriks, L., and Broeckhoven, C. (1997) Hum. Mol. Genet. 5, 1449-1455[Abstract]
103. Rohan de Silva, H. A., and Patel, A. J. (1997) Neuroreport 8, 1-12
104. Citron, M., Westaway, D., Xia, W., Carlson, G., Diehl, T., Levesque, G., Johnson-Wood, K., Lee, M., Seubert, P., Davis, A., Kholodenko, D., Motter, R., Sherrington, R., Perry, B., Yao, H., Strome, R., Lieberburg, I., Rommens, J., Kim, S., Schenk, D., Fraser, P., St George, H. P., and Selkoe, D. J. (1997) Nat. Med. 3, 67-72[Medline] [Order article via Infotrieve]
105. Hardy, J. (1997) Trends Neurosci. 20, 154-159[CrossRef][Medline] [Order article via Infotrieve]
106. Nakai, T., Yamasaki, A., Sakaguchi, M., Kosaka, K., Mihara, K., Amaya, Y., and Miura, S. (1999) J. Biol. Chem. 274, 23647-23658[Abstract/Free Full Text]
107. Xia, W., Zhang, J., Perez, R., Koo, E. H., and Selkoe, D. J. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 8208-8213[Abstract/Free Full Text]
108. Takashima, A., Sato, M., Mercken, M., Tanaka, S., Kondo, S., Honda, T., Sato, K., Murayama, M., Noguchi, K., Nakazato, Y., and Takahashi, H. (1997) Biochem. Biophys. Res. Commun. 227, 423-426[CrossRef]
109. Lah, J. J., Heilman, C. J., Nash, N. R., Rees, H. D., Yi, H., Counts, S. E., and Levey, A. I. (1997) J. Neurosci. 17, 1971-1980[Abstract/Free Full Text]
110. Thinakaran, G., Borchelt, D., Lee, M., Slunt, H., Spitzer, L., Kim, G., Ratovitsky, T., Davenport, F., Norstedt, C., Seeger, M., Hardy, J., Levey, A., Gandy, S., Jenkins, N., Copeland, N., Price, D., and Sisodia, D. (1997) Neuron 17, 181-190
111. Capell, A., Grunberg, J., Pesold, B., Diehlmann, A., Citron, M., Nixon, R., Beyreuther, K., Selkoe, D. J., and Haass, C. (1998) J. Biol. Chem. 273, 3205-3211[Abstract/Free Full Text]
112. Li, Y. M., Lai, M. T., Xu, M., Huang, Q., DiMuzio-Mower, J., Sardana, M. K., Shi, X. P., Yin, K. C., Shafer, J. A., and Gardell, S. J. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 6138-6143[Abstract/Free Full Text]
113. Ray, W. J., Yao, M., Mumm, J., Schroeter, E. H., Saftig, P., Wolfe, M., Selkoe, D. J., Kopan, R., and Goate, A. M. (1999) J. Biol. Chem. 274, 36801-36807[Abstract/Free Full Text]
114. Lichtenthaler, S. F., Wang, R., Grimm, H., Uljon, S. N., Masters, C. L., and Beyreuther, K. (1999) Proc. Natl. Acad. Sci. U. S. A.  96, 3053-3058[Abstract/Free Full Text]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.